Necroptosis modulation therapy represents an emerging treatment strategy targeting the necroptosis pathway — a programmed form of cell death mediated by receptor-interacting protein kinases (RIPK1, RIPK3) and mixed lineage kinase domain-like protein (MLKL). This therapeutic approach aims to prevent excessive neuronal death and neuroinflammation in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1][2].
Necroptosis is a caspase-independent, regulated necrotic cell death pathway that shares features with both apoptosis and necrosis. The core molecular machinery involves:
| Component | Function | Role in Neurodegeneration |
|---|---|---|
| RIPK1 (Receptor-Interacting Protein Kinase 1) | Initiates necroptosis signaling | Promotes neuronal inflammation and death |
| RIPK3 (Receptor-Interacting Protein Kinase 3) | Mediates downstream signaling | Executes necroptotic cell death |
| MLKL (Mixed Lineage Kinase Domain-Like) | Final effector of necroptosis | Causes plasma membrane rupture |
The pathway is activated by death receptor ligands (TNF-α, FasL, TRAIL), Toll-like receptor activation, and certain viral infections. Once activated, RIPK1 phosphorylates RIPK3, which then phosphorylates MLKL, causing its oligomerization and translocation to the plasma membrane where it executes cell death[3].
Alzheimer's Disease:
Parkinson's Disease:
Amyotrophic Lateral Sclerosis:
| Compound | Target | Evidence | Development Stage |
|---|---|---|---|
| Necrostatin-1 | RIPK1 | Protects neurons in AD/PD models | Preclinical |
| Ponatinib | RIPK1/3 | FDA-approved, neuroprotective | Repurposed |
| Dabrafenib | RIPK3 | Blocks necroptosis in ALS models | Preclinical |
| GSK'840 | RIPK1 | Reduces neuroinflammation | Preclinical |
| Emricasan | Pan-caspase/inflammation | Clinical trials for ALS | Phase 2 |
As of 2025, necroptosis modulation therapy remains primarily in preclinical development for neurodegenerative diseases. However, several clinical trials are underway:
| Trial | Compound | Target | Phase | Status |
|---|---|---|---|---|
| NCT05733520 | E ones | RIPK1 | Phase 1 | Recruiting |
| NCT05399099 | SAR-443122 | RIPK1 | Phase 1 | Completed |
RIPK1 inhibitors have demonstrated acceptable safety profiles in early clinical trials for inflammatory conditions. The main concern for neurodegenerative applications is ensuring adequate CNS exposure while maintaining systemic safety[8].
Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nature Reviews Neuroscience. 2019. ↩︎
Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease. ACS Chemical Neuroscience. 2022. ↩︎
RIPK1 mediates axonal degeneration by promoting inflammation. Science. 2016. ↩︎
Necroptosis and Alzheimer's Disease: Pathogenic Mechanisms and Therapeutic Targets. Journal of Alzheimer's Disease. 2023. ↩︎
Programmed Cell Death and Its Therapeutic Implications in Parkinson's Disease. Clinical Anatomy. 2025. ↩︎
Necroptosis in ALS: a hot topic in-progress. Cell Death Discovery. 2021. ↩︎
Therapeutic implications of necroptosis activation in Alzheimer's disease. Alzheimer's Research & Therapy. 2024. ↩︎
RIP1 inhibition protects retinal ganglion cells in glaucoma. Cell Death and Differentiation. 2025. ↩︎